Dewpoint Therapeutics
Boston
About Dewpoint Therapeutics
Dewpoint Therapeutics is a biotech company developing a drug platform that targets biomolecular condensates. Its technology uses machine-learning-based image analysis tools for visualizing condensates and offers an engine for genetically linked condensatopathy which is a collection of engineered cell lines with trackable condensates to prevent harmful protein sequestration, helping healthcare providers to have access to new therapies to address unmet needs. The company was founded in 2018 and is headquartered in Boston, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $349.5M
- Funding stage: Late Stage Venture
- Last round: Grant (Oct 2025)
- Website: dewpointx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/dewpoint-therapeutics-32883 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.